Pharmaceutical Market Europe • March 2025 • 37
APPOINTMENTS
NHS England
Sir James Mackey
NHS England has appointed Sir James Mackey as chief executive officer. Mackey has extensive leadership experience at a local, regional and national level and is currently serving as chief executive of Newcastle Hospitals NHS Foundation Trust, as well as senior responsible officer and national director of Elective Recovery. Mackey previously held the position of chief executive of Northumbria Healthcare NHS Foundation Trust and also served as chief executive of NHS Improvement and, for a period in 2023, was acting interim chief operating officer of NHS England. He was knighted in 2019 for his services to healthcare and is currently chair of the NHS customer board for procurement and supply. He succeeds Amanda Pritchard and will formally take up the position at the beginning of April.
Affinia Therapeutics
Hideo Makimura
Affinia Therapeutics has appointed Hideo Makimura as chief medical officer. Makimura most recently served as global vice president and head of research and development for ophthalmology at Johnson & Johnson, after serving as global vice president and head of translational and experimental medicine for cardiometabolic disease at the company.
Epitopea
Klaus Edvardsen
Epitopea has appointed Klaus Edvardsen as chief medical officer. Edvardsen takes on the role after serving as chief development officer at Nykode Therapeutics. Prior to this, he was chief development officer and chief medical officer at CureVac, and also served as senior vice president and head of global oncology development at Merck Healthcare KGaA.
Eleva
Martin Bauer
Eleva has appointed Martin Bauer as chief medical officer. Bauer joins Eleva with over two decades of clinical development experience and more recently served as senior director at Merck KGaA. Prior to this, he was head of clinical research at Basilea Pharmaceutica, medical director at ICON and also held roles at Otsuka and Boehringer Ingelheim.
Ona Therapeutics
Jutta Amersdorffer
Ona Therapeutics has appointed Jutta Amersdorffer as chief medical officer. Amersdorffer previously held multiple managerial positions at Sandoz, culminating in the role of head clinical and medical development small molecules. She also previously held roles at Hexal, Otsuka Novel Products, MorphoSys and Bencard Allergie.
Ona Therapeutics
Aleix Prat
Ona Therapeutics has appointed Aleix Prat as chair of its advisory board. Prat brings significant industry experience to the role. He is the co-founder and chief scientific officer of Reveal Genomics, and also currently serves as director of the Clínic Barcelona Comprehensive Cancer Center and professor of Medicine at the University of Barcelona.
LoQus23 Therapeutics
Cyrus Mozayeni
LoQus23 Therapeutics has appointed Cyrus Mozayeni as chair of its board of directors. Mozayeni is currently serving as president and chief executive officer of Pheon Therapeutics. He previously launched Vedere Bio and served as the company's president and chief executive office from inception until it was acquired by Novartis.
ReAlta Life Sciences
Andrew Miller
ReAlta Life Sciences has appointed Andrew Miller to its board of directors. Miller previously founded Karuna Therapeutics and served as the company’s president of research and development until it was acquired by Bristol Myers Squibb last year. He also previously held senior and executive level positions at PureTech Health, Tal Medical and Entrega.
Dermaliq Therapeutics
Ralf Paus
Dermaliq Therapeutics has appointed Ralf Paus to its scientific and medical advisory board. Paus currently serves as research professor of dermatology at the University of Miami Miller School of Medicine and is an academic dermatologist with over 35 years of experience in dermatology and skin and hair research. He is also the founder and chief executive officer of Cutaneon.
Pharmaceutical Market Europe (PME)
Pharmaceutical industry news, articles, jobs, reports, advice and services